Key Insights

Highlights

Success Rate

83% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 39/100

Termination Rate

10.5%

2 terminated out of 19 trials

Success Rate

83.3%

-3.2% vs benchmark

Late-Stage Pipeline

26%

5 trials in Phase 3/4

Results Transparency

60%

6 of 10 completed with results

Key Signals

6 with results83% success

Data Visualizations

Phase Distribution

17Total
Not Applicable (4)
P 1 (4)
P 2 (4)
P 3 (5)

Trial Status

Completed10
Unknown3
Active Not Recruiting2
Terminated2
Not Yet Recruiting1
Recruiting1

Trial Success Rate

83.3%

Benchmark: 86.5%

Based on 10 completed trials

Clinical Trials (19)

Showing 19 of 19 trials
NCT07516561Phase 3Not Yet RecruitingPrimary

Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia

NCT05910450Phase 3Active Not RecruitingPrimary

A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss

NCT05914805Phase 3CompletedPrimary

A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2)

NCT05802173Phase 2CompletedPrimary

Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia

NCT07011485Phase 2Active Not RecruitingPrimary

A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia.

NCT06854432Not ApplicableTerminatedPrimary

Assessment of Biological and Biometrological Parameters in Adult Subjects with Androgenetic Alopecia

NCT06263413Recruiting

Clinical Workflow Optimization Using Artificial Intelligence for Dermatological Conditions

NCT05244980Phase 1CompletedPrimary

A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)

NCT05681897Not ApplicableUnknownPrimary

Comparing Platelet-Rich Plasma (PRP) Centrifugation Methods on Thrombocyte Concentration and Clinical Improvement of Androgenetic Alopecia

NCT04913519Phase 1CompletedPrimary

A Phase 1 Study of TDM-105795 Topical Solution in Male Subjects With Androgenetic Alopecia (AGA)

NCT05296863Phase 3CompletedPrimary

Adipose-derived Stem Cell Conditioned Media as a Novel Approach for Hair Regrowth in Male Androgenetic Alopecia

NCT02503852Not ApplicableCompletedPrimary

STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia

NCT03004469Phase 3CompletedPrimary

Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia

NCT03154528UnknownPrimary

Role of Vitamin D in Androgenetic Alopecia

NCT02676310Phase 1Terminated

Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)

NCT02316418Not ApplicableUnknown

Hairstetics™ Anchoring System in Female Pattern Hair Loss (HAS-FPHL)

NCT01904721Phase 2Completed

A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)

NCT01325337Phase 2Completed

Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia

NCT01189279Phase 1Completed

Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia

Showing all 19 trials

Research Network

Activity Timeline